Asset Details
Do you wish to reserve the book?
Response to: ‘Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis’ by Mathieu et al
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Response to: ‘Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis’ by Mathieu et al
Do you wish to request the book?
Response to: ‘Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis’ by Mathieu et al
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Response to: ‘Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis’ by Mathieu et al
2018
Overview
Correspondence to Dr Charlotte Hua, Department de Rheumatology, Lapeyronie Hospital, Montpellier 34295, France; c-hua@chu-montpellier.fr In their letter to the editor, Mathieu1 and colleagues provide information that reinforce the conclusions of our recent paper.2 3 We appreciate their interest in our study and complement the authors for their systematic review and meta-analysis of cardiovascular (CV) effects of hydroxychloroquine (HCQ) in rheumatoid arthritis (RA), lupus and other diseases. [...]their results are concordant with ours, highlighting notably a decrease of over 50% of diabetes occurrence in the HCQ group. [...]including more studies has allowed them to perform a meta-analysis for the occurrence of CV events, which we were not able to do, confirming the lower frequency of CV events in the HCQ group. [...]we were aware that the lower CV risk noted for the patients belonging to the ‘HCQ users’ was perhaps linked to the characteristics of these patients’ disease and not to the HCQ treatment in itself.
Publisher
Elsevier B.V,Elsevier Limited
